STK39 Mouse anti-Human, Clone: OTI4H3, Invitrogen
Mouse Monoclonal Antibody
Manufacturer: Invitrogen MA524935
DescriptionThe serine/threonine kinase Stk39 belongs to the STE20 family, a group of kinases that are known to interact with inflammation-related kinases (such as p38, JNK, NKCC1, PKC-theta, WNK and MLCK), and with transcription factor AP-1. The STE 20 family is involved in diverse biological phenomena, including cell differentiation, cell transformation/ proliferation, cytoskeleton rearrangement, and the regulation of ion transporters. STK39 contains an N-terminal series of proline and alanine repeats (PAPA box), followed by a serine/threonine kinase catalytic domain and is abundantly expressed in the brain. STK39 is activated in response to hypotonic stress, leading to phosphorylation of several cation-chloride-coupled co-transporters. The catalytically active kinase specifically activates the p38 MAP kinase pathway, and its interaction with p38 decreases upon cellular stress, suggesting that this kinase may serve as an intermediate in the response to cellular stress. Recent studies show that STK39 tend to be a novel candidate gene for autism and hypertension.
|PBS with 1% BSA, 50% glycerol and 0.02% sodium azide; pH 7.3|
|STE20/SPS1 homolog; STE20/SPS1-related proline-alanine-rich protein kinase; Ste20-like protein kinase; proline-alanine-rich STE20-related kinase; serine threonine kinase 39 (STE20/SPS1 homolog, yeast); serine/threonine-protein kinase 39; small intestine SPAK-like kinase; ste-20-related kinase|
|-20° C, Avoid Freeze/Thaw Cycles|
|Flow Cytometry, Immunocytochemistry, Immunofluorescence, Immunohistochemistry (Paraffin), Western Blot|
|Full length human recombit protein of STK39 produced in HEK293T cell|
We continue to work to improve your shopping experience and your feedback regarding this content is very important to us. Please use the form below to provide feedback related to the content on this product.
Your feedback has been submitted. Fisher Scientific is always working to improve our content for you. We appreciate your feedback.Ok